ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 08/04/22

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2022 Results Conference Call August 4, 2022 05:00 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President and CEO Javier San Martin - Chief Medical Officer Ken Myszkowski - CFO James Ha...

Arrowhead Pharmaceuticals press release ( NASDAQ: ARWR ): FQ3 GAAP EPS of -$0.68 misses by $0.21 . Revenue of $32.41M (-29.4% Y/Y) misses by $20.2M . During the quarter, the company formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the r...

- Conference Call and Webcast Today, August 4, 2022 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022. The company is hosting a conference call today, August 4, 2022, at 4:30 p.m. ET ...

My portfolio, built specifically for my retirement ~20+ years from now, benefits from a surprise Petrobras gift. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retirement egg. A po...

Shares of RNA interference concern Arrowhead Pharmaceuticals are down over 50% since making an all-time high in June 2021. The company’s approach has been validated by its four licensing deals, rival Alnylam’s commercial success, and Novo Nordisk’s buyout of RNAi ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022. Conference Call and Webcast Details Invest...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) appointed Patrick O'Brien as COO and General Counsel, effective July 15, 2022. He will continue to perform the functions of Chief Compliance Officer and Corporate Secretary; Mr. O’Brien joined the company in ...

Cowen has upgraded Takeda Pharmaceutical Company ( NYSE: TAK ) to outperform from market perform to outperform citing the Japanese pharma's current valuation, dividend yield, and cash flow. The firm upped its price target to $24 from $21 (~67% upside based on Monday's clos...

Gainers: Burning Rock Biotech ( BNR ) +4% . TripAdvisor  ( TRIP ) +2% . comScore ( SCOR ) +2% . Arrowhead Pharmaceuticals ( ARWR ) +2% . Bolt Biotherapeutics ( BOLT ) +2% . Losers: Swvl Holdings  ( SWVL ) ...

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) said it dosed the first patients in two phase 1/2a trials of its RNA interference candidates ARO-MUC5AC and ARO-RAGE, being explored to treat certain muco-obstructive and inflammatory pulmonary diseases. A phase 1/2a stud...